コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mug three times weekly for 96 weeks.
2 domly assigned in a 2:1 ratio to receive either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) or pla
4 essed the effect of lipopolysaccharide (LPS) administration at a dose of 2 ng/kg of body weight on motivation in 21 healt
5 afety of pembrolizumab, a humanized PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in relapsed and transformed
6 e at high risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 weeks o
8 controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4
9 eive either antiandrogen therapy (24 months of bicalutamide at a dose of 150 mg daily) or daily placebo tablets during an
10 438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo.
11 th BRAF V600E or V600K mutations to receive oral dabrafenib at a dose of 150 mg twice daily plus trametinib at a dose of
12 f body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group
13 0 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily fo
14 feeding to receive either an enteral emulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a c
15 eight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneou
16 nts to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months
17 to reduce phase 2 flinching in the mouse formalin test even at a dose of 100 mpk PO due to insufficient dorsal root gangl
18 ceive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly.
20 ized to a MVA-5T4 group received an intramuscular injection at a dose of 1 x 109 50% tissue culture infectious dose on tr
21 a A, the complex normalized hemostasis upon vascular injury at a dose of 0.3 nmol/kg compared with 300 nmol/kg for FVIIa.
22 ve relatives of patients with type 1 diabetes, oral insulin at a dose of 7.5 mg/d, compared with placebo, did not delay o
23 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 we
24 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses p
25 a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses,
27 ndomly assigned to receive either intravenous levosimendan (at a dose of 0.2 mug per kilogram of body weight per minute f
29 of 0.015, 0.045, or 0.075 mg per kilogram) or once monthly (at a dose of 0.225, 0.45, 0.9, or 1.8 mg per kilogram or a fi
30 ilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a
31 previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab
32 mab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or
33 nitro-4-trifluoromethylbenzoyl)-1, 3 cyclohexandione (NTBC) at a dose of 1 mg/kg per day initially after birth.
34 -limiting toxic effects of rovalpituzumab tesirine occurred at a dose of 0.8 mg/kg every 3 weeks, including grade 4 throm
35 psing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon
36 amphotericin B deoxycholate (amphotericin) (219 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight per da
37 dy weight per day, or itraconazole capsules (221 patients), at a dose of 600 mg per day for 3 days, followed by 400 mg pe
38 lisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose
39 rage score reported during induction (ipilimumab or placebo at a dose of 10 mg/kg, administered as one single dose at the
40 Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days
41 tarting dose of 90 mg per week: three patients were started at a dose of 450 mg per week, three at 360 mg per week, 19 at
42 We investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-surface area adm
43 s, in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other week, combined wit
45 dabrafenib at a dose of 150 mg twice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patien
46 ic promoter and factor IX Padua (factor IX-R338L) transgene at a dose of 5x10(11) vector genomes per kilogram of body wei
47 ceive a continuous intravenous infusion of either ularitide at a dose of 15 ng per kilogram of body weight per minute or
48 Here, we conducted an open-label trial with PfSPZ Vaccine at a dose of 9.0 x 10(5) PfSPZ administered i.v. three times
50 ee injections of fitusiran administered either once weekly (at a dose of 0.015, 0.045, or 0.075 mg per kilogram) or once
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。